Martinsried/Munich, Germany, October 15, 2010 - MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that its research and diagnostic antibodies unit AbD Serotec has signed a two year contract for the supply of custom monoclonal antibodies with Research Councils UK Shared Services Centre Limited (RCUK SSC Ltd). RCUK SSC Ltd has been set up by the seven Research Councils of the UK (RCUK) to provide centralized services to the Research Councils and their institutes in various areas including procurement.
“We are delighted that RCUK SSC Ltd has selected AbD Serotec as one of their service providers of choice,” says Dieter Feger, Head of AbD Serotec. "By signing this two year contract, RCUK SSC Ltd confirms their trust in our HuCAL technology and the outstanding service with which AbD Serotec as a division of MorphoSys AG has positioned itself successfully within the biotechnology community.”
Richard Fowles, Category Manager with RCUK SSC Ltd commented, “We are very pleased to be able to announce that AbD Serotec is to be one of our preferred suppliers of custom monoclonal antibodies. We feel that their great product offering will be of significant benefit to our researchers, especially since the use of their system obviates the use of animals as a source of research antibodies.”
HuCAL stands for Human Combinatorial Antibody Library, a unique collection of billions of recombinant human Fab antibodies which mimics the entire human antibody repertoire. It is an integral part of a sophisticated system that has been proven to deliver highly specific antibodies for all classes of antigens, without the use of animals. HuCAL technology was developed by MorphoSys and is one of the most powerful methods available for generating fully human antibodies for research, diagnostic and therapeutic applications.
MorphoSys is an independent biotechnology company that develops novel antibodies for therapeutic, diagnostic and research applications. The Company's HuCAL technology is one of the most powerful methods available for generating fully human antibodies. By successfully applying this and other proprietary technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human health-care. Through its alliances with some of the world's leading pharmaceutical companies, MorphoSys has created a pipeline of more than 60 drug candidates. The Company is expanding its drug pipeline by adding new partnered programs, and by building a portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio, the Company is focused on the areas of oncology and inflammation. Its most advanced program MOR103, a first-in-class, fully human antibody against GM-CSF, is currently tested in a Phase Ib/IIa trial in rheumatoid arthritis patients. Via its business unit AbD Serotec, MorphoSys is expanding the reach of its technologies in the diagnostics and research markets. MorphoSys is headquartered in Munich, Germany and listed on the Frankfurt Stock Exchange under the symbol "MOR". For further information, visit http://www.morphosys.com
HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R) and RapMAT(R) are registered trademarks of MorphoSys.
About Research Councils UK (RCUK):
RCUK SSC Ltd is a separate legal entity, wholly owned by the seven UK Research Councils working in partnership as RCUK. The Shared Services Centre (SSC) will serve all the Research Councils by providing:
• Integrated, efficient and responsive single organisation administrative support service;
• Greater value for money;
• A clearer, consistent customer focus.
RCUK SSC Ltd represents the continuation of plans to increase operational efficiency and effectiveness through joint services. It employs IRO 600 people and is organised and run on a commercial basis incorporating the following business areas: Human resources; Finance; Procurement; IT and telecommunications; Grants processing, including fellowships and studentships.
Every penny saved over the years to come, is a penny more available to spend on research and development for UK businesses. The aim is to save GBP 450 million over the next 10 years.
Further details can be found at: http://www.ssc.rcuk.ac.uk
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.
ANDREW LLOYD & ASSOCIATES
Brighton Business Centre 95 Ditchling Road Brighton BN1 4ST ENGLAND
Tel: +44 1273 675100 Fax: +44 1273 675400
55 rue Boissonade 75014 Paris FRANCE
Tel: +33 1 56 54 07 00 Fax: +33 1 56 54 07 01
INTERNATIONAL TECHNOLOGY MARKETS, STRATEGY & COMMUNICATION